Skip to main content

Table 1 Characteristics of patient series (n = 31)

From: Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

Median age, years (range)

64 (28–85)

Gender, n (%)

   male

18 (58)

   female

13 (42)

ECOG PS, n (%)

   0

3 (9.7)

   1

16 (51.6)

   2

8 (25.8)

   3

4 (12.9)

Histology, n (%)

   squamous

10 (32.3)

   adenocarcinoma

20 (64.5)

   unspecified

1 (3.2)

TNM staging, n (%)

   IIIa

1 (3.2)

   IIIb

4 (12.9)

   IV

26 (83.9)

Prior chemotherapy, n (%)

 

   1 regimen

5 (16.1)

   2 regimens

10 (32.3)

   ≥3 regimens

16 (51.6)

  1. ECOG, Eastern Cooperative Oncology Group; PS, performance status